Well-differentiated hand liposarcoma with bone metastases treated successfully with zoledronic acid

Onkologie

Volumn 34, Issue 12, 2011, Pages 706-709

  Mystakidou, Kyriaki ^a   Panagiotou, Irene ^a   Brountzos, Elias ^b   Kouloulias, Vassilios ^b   Gouliamos, Athanasios ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bisphosphonates; Bone metastases; Liposarcomas; Local recurrence; Zoledronic acid

Indexed keywords

CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DICLOFENAC; FENTANYL; ZOLEDRONIC ACID;

ADULT; ARTICLE; BACKACHE; BONE METASTASIS; BONE SCINTISCANNING; CALCIUM BLOOD LEVEL; CASE REPORT; DRUG DOSE TITRATION; EXTERNAL BEAM RADIOTHERAPY; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; LIPOSARCOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; TUMOR DIFFERENTIATION; TUMOR RECURRENCE;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HAND; HUMANS; IMIDAZOLES; LIPOSARCOMA; MALE; MIDDLE AGED; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME;

EID: 83755220534     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000334551     Document Type: Article

References (25)

1. Laurino L, Furlanetto A, Orvieto E, Dei Tos AP: Well-differentiated liposarcoma (atypical lipomatous tumors). Semin Diagn Pathol 2001;18:258-262. (Pubitemid 33089752)
2. Brien EW, Terek RM, Geer RJ, Caldwell G, Brennan MF, Healey JH: Treatment of soft-tissue sarcomas of the hand. J Bone Joint Surg Am 1995; 77:564-571.
3. Cribb GL, Cool WP, Ford DJ, Mangham DC: Giant lipomatous tumours of the hand and forearm. J Hand Surg Br 2005;30:509-512. (Pubitemid 41194694)
4. Ogose A, Kobayashi H, Morita T, Hasegawa K, Hirata Y: Well-differentiated liposarcoma of the hand. Case report. Scand J Plast Reconstr Surg Hand Surg 2000;34:185-187. (Pubitemid 30495411)
5. Bailey SC, Bailey B, Smith NT, Van Tassel P, Thomas CR Jr: Brain metastasis from a primary liposarcoma of the digit: case report. Am J Clin Oncol 2001;24:81-84. (Pubitemid 32178677)
6. Murray PM: Soft tissue sarcoma of the upper extremity. Hand Clin 2004;20:325-333. (Pubitemid 38954043)
7. Stresing V, Daubiné F, Benzaid I, Mönkkönen H, Clézardin P: Bisphosphonates in cancer therapy. Cancer Letters 2007;257:16-35. (Pubitemid 47464698)
8. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R; ABCSG-12 Trial Investigators, Marth C: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-691.
9. Zarogoulidis K, Boutsikou E, Zarogoulidis P, Eleftheriadou E, Kontakiotis T, Lithoxopoulou H, Tzanakakis G, Kanakis I, Karamanos NK: The impact of zoledronic acid therapy on survival of lung cancer patients with bone metastasis. Int J Cancer 2009;125:1705-1709.
10. Zagars GK, Goswitz MS, Pollack A: Liposarcoma: outcome and prognostic factors following conservation surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1996;36:311-319. (Pubitemid 26359454)
11. Guadagnolo BA, Zagars GK, Ballo MT, Patel SR, Lewis VO, Benjamin RS, Pollock RE: Excellent local control rates and distinctive patterns of failure in myxoid liposarcoma treated with conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:760-765. (Pubitemid 351199710)
12. Schwab JH, Boland P, Guo T, Brennan MF, Singer S, Healey JH, Antonescu CR: Skeletal metastases in myxoid liposarcoma: an unusual pattern of distant spread. Ann Surg Oncol 2007;14:1507-1514. (Pubitemid 46536828)
13. Fleish H: Development of bisphosphonates. Breast Cancer Res 2002;4:30-34.
14. Mystakidou K, Katsouda E, Tsilika E, Vlahos L: Bone metastases responding to bisphosphonate treatment: two case reports of patients with solid tumours. J Cancer Inter Med 2005;3:85-90. (Pubitemid 43329865)
15. Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J: The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2002;20 (suppl 2):45-54. (Pubitemid 35303443)
16. Bosch-Barrera J, Merajver SD, Menéndez JA, Van Poznak C: Direct antitumour activity of zoledronic acid: preclinical and clinical data. Clin Transl Oncol. 2011;13:148-155.
17. Heymann D, Ory B, Gouin F, Green JR, Redini F: Bisphoshonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med. 2004;10:337-343. (Pubitemid 38881523)
18. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F: Zoledronic acid suppresses lung metastases and prolongs survival of osteosarcoma-bearing mice. Cancer 2005;104:2522-2529. (Pubitemid 41691577)
19. Dass CR, Choong PF: Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol Cancer Ther 2007;6:3263-3270.
20. Mahtani R, Khan R, Jahanzeb M: The potential application of zoledronic acid as anticancer therapy patients with non-small-cell lung cancer. Clin Lung Cancer. 2011;12:26-32.
21. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Study Group: First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376:1989-1999.
22. Iguchi T, Miyakawa Y, Saito K, Nakabayashi C, Nakanishi M, Saya H, Ikeda Y, Kizaki M: Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells. Int J Oncol 2007;31:285-291.
23. Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, Redini F: Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res 2010;70:7610-7619.
24. Muraro M, Mereuta OM, Carraro F, Madon E, Fagioli F: Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells. Cell Immunol 2007;249:63-72.
25. Gouin F, Ory B, Rédini F, Heymann D: Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curettage and increases overall survival. Int J Cancer 2006;119:980-984. (Pubitemid 44116903)